| Title |
Nivolumab: A Review of Its Use in Patients with Malignant Melanoma
|
|---|---|
| Published in |
Drugs, July 2014
|
| DOI | 10.1007/s40265-014-0234-4 |
| Pubmed ID | |
| Authors |
Emma D. Deeks |
| Abstract |
Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous nivolumab to be used in the treatment of advanced malignancies such as melanoma was initially demonstrated in phase I dose-ranging trials. Subsequently, in a noncomparative, open-label, phase II trial, almost one-quarter of Japanese patients with previously treated stage III/IV melanoma (recurrent or unresectable) achieved a partial tumour response with intravenous nivolumab 2 mg/kg every 3 weeks. The clinical benefit of the drug was durable, with patients surviving free from progression for a median of 172 days and median overall survival not yet reached. Nivolumab had an acceptable tolerability profile in this trial, with fewer than 18 % of patients experiencing grade 3 or 4 adverse events related to the drug, the most common of which was increased γ-glutamyl transferase. Thus, nivolumab is an emerging, promising option for the treatment of malignant melanoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 1% |
| Unknown | 82 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 16% |
| Researcher | 12 | 14% |
| Student > Master | 12 | 14% |
| Student > Bachelor | 10 | 12% |
| Other | 5 | 6% |
| Other | 11 | 13% |
| Unknown | 20 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 28% |
| Biochemistry, Genetics and Molecular Biology | 11 | 13% |
| Agricultural and Biological Sciences | 10 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Immunology and Microbiology | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 22 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#6,646,567
of 23,485,204 outputs
Outputs from Drugs
#1,142
of 3,314 outputs
Outputs of similar age
#61,692
of 228,509 outputs
Outputs of similar age from Drugs
#13
of 37 outputs
Altmetric has tracked 23,485,204 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 3,314 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,509 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.